Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of QRL-101 in Healthy Participants
NCT07421778Phase 1Completed
- Sponsor
- QurAlis
- Start
- Feb 2026
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing QRL-101 with Placebo (2 arms). Primary endpoint: Safety and tolerability at Day 29. Started Feb 2026; status: completed.
02
Drugs
QRL-101
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07421778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07421778.